Jiangsu Hengrui Pharmaceuticals(600276.SH): HRS-8797 tablets obtain approval notice for clinical trials of new drugs.
Hengrui Medicine (600276.SH) announced that its subsidiary Chengdu Shengdi Pharmaceutical Co., Ltd. recently received the Drug Clinical Trial Approval Notification issued by the National Medical Products Administration for HRS-8797 tablets, and will soon begin clinical trials.
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Chengdu Shengdi Pharmaceuticals Co., Ltd., recently received approval from the National Medical Products Administration for the clinical trial of HRS-8797 tablets. The clinical trials will be conducted in the near future.
HRS-8797 tablet is a type 1 innovative drug developed independently by the company for the treatment of atopic dermatitis. According to the search, there are currently no similar drugs approved for marketing worldwide. As of now, the accumulated research and development investment for the HRS-8797 tablet project is approximately 32.9 million yuan (unaudited).
Related Articles
Great Wall Motor (02333) spent 3.037 million Hong Kong dollars to repurchase 35.05 million shares on July 15th.
CHINA SOUTH AIR(01055): Passenger transport capacity in June decreased by 1.18% year-on-year.
On July 15, C-MER MEDICAL (03309) spent HKD 134,300 to repurchase 140,000 shares.
Great Wall Motor (02333) spent 3.037 million Hong Kong dollars to repurchase 35.05 million shares on July 15th.
CHINA SOUTH AIR(01055): Passenger transport capacity in June decreased by 1.18% year-on-year.
On July 15, C-MER MEDICAL (03309) spent HKD 134,300 to repurchase 140,000 shares.
RECOMMEND
